Berkshire Hathaway Inc. (BRK-B) vs Merck & Co., Inc. (MRK)

See how Berkshire Hathaway Inc. and Merck & Co., Inc. differ across market data and performance, so you can decide which asset best fits your strategy.

$499.84
NYSE
View Full Page
$152.23
NYSE
Merck & Co., Inc. develops pharmaceutical products across multiple therapeutic areas, including cardiometabolic disorders, oncology, and infectious diseases. In cancer treatment, its immuno-oncology portfolio, led by Keytruda, represents a significant driver of total revenue. The company also maintains a strong vaccines business focused on preventing pediatric illnesses, alongside Gardasil for human papillomavirus. In addition, Merck markets animal health products. Geographically, 47% of the company’s sales come from its U.S. human health segment, which includes pharmaceuticals and vaccines.
View Full Page

Key Metrics Comparison

Berkshire Hathaway Inc.BRK-B
Market Cap
$1.07T
Price
$499.84
24h Change
-0.62%
24h Volume
$2.74M
Employees
387,800
Shares Outstanding
N/A
Merck & Co., Inc.MRK
Market Cap
$375.578B
Price
$152.23
24h Change
+12.62%
24h Volume
$29.34M
Employees
73,000
Shares Outstanding
2,469,879,206

Category Performance

Visual comparison across key categories. Ring fill represents relative strength or share between the two assets.

Market Share

Share of combined market cap

Market Share
BRK-B
74.0%
MRK
26.0%

Volume Share

Share of combined 24h volume

Volume Share
BRK-B
8.5%
MRK
91.5%

24h Performance

Price change over last 24 hours

24h Performance
BRK-B
-0.62%
MRK
12.62%
Price Comparison
Berkshire Hathaway Inc.
Merck & Co., Inc.